AstraZeneca AZN and Japan-based partner Daiichi Sankyo announced that the FDA has accepted a supplemental biologics license application (sBLA), which seeks label expansion for their blockbuster ...
Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Monday granted a ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29 ...
AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.
Enhertu and Perjeta combination shows promise in extending progression-free survival for HER2-positive breast cancer, potentially redefining first-line treatment. Personal narratives highlight the ...
AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for first-line use in breast cancer.
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Dec 15 (Reuters) - The U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results